Mirati Therapeutics, Inc. (NASDAQ:MRTX) Files An 8-K Regulation FD Disclosure

On September 14, 2017, Mirati Therapeutics, Inc. issued a press release announcing the presentation of preliminary data from two ongoing clinical trials of sitravatinib in non-small cell lung cancer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

The information furnished on this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01Financial Statements and Exhibits.

(d) Exhibits.

Mirati Therapeutics, Inc. ExhibitEX-99.1 2 iaslcchicagodata.htm EXHIBIT 99.1 Exhibit Exhibit 99.1MIRATI THERAPEUTICS PRESENTS POSITIVE PRELIMINARY DATA FROM ON-GOING CLINICAL TRIALS OF SITRAVATINIB IN NON-SMALL CELL LUNG CANCER  •Combination of sitravatinib and nivolumab in NSCLC patients with documented progression following checkpoint therapy demonstrated 3 confirmed Partial Responses in first 11 evaluable patients•First evaluable NSCLC patient with CBL inactivating mutation treated with single agent sitravatinib demonstrated confirmed Partial Response with 77% tumor reductionSAN DIEGO - September 14,…To view the full exhibit click here